| Literature DB >> 28526555 |
Gad D Vatine1, Abraham Al-Ahmad2, Bianca K Barriga1, Soshana Svendsen1, Ariel Salim1, Leslie Garcia1, Veronica J Garcia1, Ritchie Ho1, Nur Yucer1, Tongcheng Qian3, Ryan G Lim4, Jie Wu5, Leslie M Thompson6, Weston R Spivia7, Zhaohui Chen7, Jennifer Van Eyk7, Sean P Palecek3, Samuel Refetoff8, Eric V Shusta9, Clive N Svendsen10.
Abstract
Inactivating mutations in the thyroid hormone (TH) transporter Monocarboxylate transporter 8 (MCT8) cause severe psychomotor retardation in children. Animal models do not reflect the biology of the human disease. Using patient-specific induced pluripotent stem cells (iPSCs), we generated MCT8-deficient neural cells that showed normal TH-dependent neuronal properties and maturation. However, the blood-brain barrier (BBB) controls TH entry into the brain, and reduced TH availability to neural cells could instead underlie the diseased phenotype. To test potential BBB involvement, we generated an iPSC-based BBB model of MCT8 deficiency, and we found that MCT8 was necessary for polarized influx of the active form of TH across the BBB. We also found that a candidate drug did not appreciably cross the mutant BBB. Our results therefore clarify the underlying physiological basis of this disorder, and they suggest that circumventing the diseased BBB to deliver active TH to the brain could be a viable therapeutic strategy.Entities:
Keywords: MCT8; T3; blood brain barrier; disease model; iPSC; induced pluripotent stem cells; monocarboxyl transporter 8; neuronal maturation; thyroid; thyroid hormone
Mesh:
Substances:
Year: 2017 PMID: 28526555 PMCID: PMC6659720 DOI: 10.1016/j.stem.2017.04.002
Source DB: PubMed Journal: Cell Stem Cell ISSN: 1875-9777 Impact factor: 24.633